NCT02875548
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must be receiving tazemetostat as either monotherapy or in combination with other approved drug(s) or investigational agent(s)
Exclusions: 
https://ClinicalTrials.gov/show/NCT02875548